This is why psilocybin may be able to help millions

Psychedelics could offer help for millions suffering from depression. In fact, according to the Washington Examiner, researchers from The Center for Psychedelic and Consciousness Research at Johns Hopkins University, published research on psilocybin and major depressive disorder. Of the 24 patients who suffered from the disease and went through the treatment, 17 experienced declines in their depression after a month. And of those 17, 14 no longer experienced depression.” Those findings could be beneficial for psychedelic companies, such as MYND Life Sciences Inc. (CSE:MYND), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Wesana Health Holdings (CSE:WESA)(OTC:DBDID), Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF), and Mind Cure Health (CSE:MCUR)(OTC:MCURF).

In addition, as also noted by the Washington Examiner, Matthew Johnson, a professor of psychiatry and behavioral sciences at the Hopkins center, has said, “Psilocybin works by activating the serotonin 2a receptors in the brain, receptors that are linked to mental illness.” That being the case, it may only be a matter of time before psychedelics become a go-to treatment for millions suffering with some sort of mental issues.